Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL19235640 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19526092 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6761683 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17858716 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12503065 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL249738 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9143689 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285577-A1 | POLYSACCHARIDE DERIVATIVE, POLYSACCHARIDE DERIVATIVE-DRUG CONJUGATE, AND METHOD FOR PRODUCING SAME | THE UNIVERSITY OF TOKYO (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | IGM BIOSCIENCES, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230132256-A1 | COMBINATION THERAPY | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2023-04-27 | — | — | US | disclosed |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-12-15 | — | — | US | disclosed |
| US-20220281904-A1 | A PRODRUG PLATFORM USEFUL TO DELIVER AMINES, AMIDES AND PHENOLS | Changchun Changcheng Pharmaceutical Technology Co., LTD (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20220193106-A1 | NUCLEOBASE ANALOGUE DERIVATIVES AND THEIR APPLICATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-06-23 | — | — | US | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| US-20220031670-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | BASILEA PHARM INT AG (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20220016243-A1 | METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY | GENENTECH, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210128736-A1 | STEREOCOMPLEX OF OLIGOLACTIC ACID CONJUGATES IN MICELLES FOR IMPROVED PHYSICAL STABILITY AND ENHANCED ANTITUMOR EFFICACY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-05-06 | — | — | US | disclosed |
| US-10960078-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20200405879-A1 | COMBINATION THERAPY | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-12-31 | — | — | US | disclosed |
| US-20200338202-A1 | SHORT TAT OLIGOMERS FOR DRUG DELIVERY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-10-29 | — | — | US | disclosed |
| US-20200262861-A1 | GEMCITABINE PRODRUGS | NUCANA BIOMED LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10544223-B2 | Combination therapy with an anti-axl antibody-drug conjugate | ADC THERAPEUTICS SA (CH) | 2020-01-28 | — | — | US | disclosed |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-11-05 | — | — | US | disclosed |
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2019-07-18 | — | — | US | disclosed |
| US-20170056506-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | UNIV SHANGHAI JIAOTONG (CN) | 2017-03-02 | — | — | US | disclosed |
| WO-2010093435-A1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING 5-AZACYTIDINE | CELGENE INTERNATIONAL SARL (CH) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132256-A1 | COMBINATION THERAPY | IL2RA, IL2, CD22 | POLA1 3814/4885PDE3A 3463/4885PDE4D 1645/4885 |
| US-20210128736-A1 | STEREOCOMPLEX OF OLIGOLACTIC ACID CONJUGATES IN MICELLES FOR IMPROVED PHYSICAL STABILITY AND ENHANCED ANTITUMOR EFFICACY | GMNN, MCTS1, OSTC | POLA1 129/4885PDE3A 2747/4885PDE4D 3142/4885 |
| US-20170056506-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | ABCB4, ABCB1, LCAT | POLA1 3077/4885PDE3A 4201/4885PDE4D 3699/4885 |
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ERBB2, ERBB3, AXL | POLA1 4292/4885PDE3A 3706/4885PDE4D 2059/4885 |
| US-20200338202-A1 | SHORT TAT OLIGOMERS FOR DRUG DELIVERY | ACIN1, MYCBP, STAT3 | POLA1 1611/4885PDE3A 4790/4885PDE4D 4716/4885 |
| US-20220193106-A1 | NUCLEOBASE ANALOGUE DERIVATIVES AND THEIR APPLICATIONS | PNLIP, NT5C2, ENPP3 | POLA1 486/4885PDE3A 775/4885PDE4D 688/4885 |
| US-20200405879-A1 | COMBINATION THERAPY | CD22, CD2, CD2BP2 | POLA1 4620/4885PDE3A 2754/4885PDE4D 1341/4885 |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | POLA1 3273/4885PDE3A 3148/4885PDE4D 2230/4885 |
| US-20220016243-A1 | METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY | ERBB2, EGFR, TNFRSF9 | POLA1 4355/4885PDE3A 4725/4885PDE4D 4274/4885 |
| US-10544223-B2 | Combination therapy with an anti-axl antibody-drug conjugate | ERBB2, ERBB3, AXL | POLA1 4292/4885PDE3A 3706/4885PDE4D 2059/4885 |
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | MCL1, BID, BAD | POLA1 222/4885PDE3A 2234/4885PDE4D 1515/4885 |
| US-20220281904-A1 | A PRODRUG PLATFORM USEFUL TO DELIVER AMINES, AMIDES AND PHENOLS | GOT1, PAM, GLS2 | POLA1 1534/4885PDE3A 1214/4885PDE4D 2303/4885 |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | ABCB4, ABCB1, LCAT | POLA1 3077/4885PDE3A 4201/4885PDE4D 3699/4885 |
| US-20230285577-A1 | POLYSACCHARIDE DERIVATIVE, POLYSACCHARIDE DERIVATIVE-DRUG CONJUGATE, AND METHOD FOR PRODUCING SAME | DDOST, ALG1, STT3B | POLA1 4245/4885PDE3A 693/4885PDE4D 914/4885 |
| US-20200262861-A1 | GEMCITABINE PRODRUGS | TYMP, PNP, MTAP | POLA1 593/4885PDE3A 823/4885PDE4D 545/4885 |
| US-10960078-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | ABCB4, ABCB1, LCAT | POLA1 3077/4885PDE3A 4201/4885PDE4D 3699/4885 |
| US-20220031670-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | KRAS, GLS, SLC28A1 | POLA1 720/4885PDE3A 949/4885PDE4D 2297/4885 |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, SAMHD1 | POLA1 314/4885PDE3A 2620/4885PDE4D 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.